Flemish Joint Effort for Biomarker PRofiling in Inflammatory Systemic Diseases

Last updated: September 5, 2024
Sponsor: University Hospital, Ghent
Overall Status: Active - Recruiting

Phase

N/A

Condition

Inflammation

Collagen Vascular Diseases

Connective Tissue Diseases

Treatment

cytokine and lipidomic profiling

Clinical Study ID

NCT05670301
BC-11141
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

A multi-centre, prospective study to study cytokine profiles and other potential disease-specific biomarkers in patients with presumed or confirmed diseases of systemic inflammation

The goal of this prospective, observational study is to describe the longitudinal evolution of blood cytokine profiles in patients with presumed or confirmed diseases of systemic inflammation

The main questions it aims to answer are:

  • What are the differences and similarities in blood cytokines between different patients and groups presenting symptoms of systemic inflammatory conditions?

  • How is the cytokine profile of individual patients evolving over time and what is the effect of different therapeutics?

  • Is cytokine profiling a valuable tool to diagnose and follow-up on patients with systemic inflammatory conditions?

Participants will be asked to give an additional blood volume for research purposes when blood sampling is performed for routine clinical purposes. A subset of patients (those initiated on biologicals) will also be asked to complete questionnaires.

Researchers will compare the blood cytokines profiles between the different groups of systemic inflammatory conditions and with healthy individuals.

Eligibility Criteria

Inclusion

Inclusion Criteria:

An individual who meets any of the following criteria can be eligible for participation in this study:

  1. Child or adult

  2. Written informed consent

  3. Suspected or confirmed disease with systemic inflammation (acute, chronic and/orrecurrent), these include:

  4. Autoinflammatory diseases (AID), including among others: systemic onsetjuvenile idiopathic arthritis (sJIA), familial mediterranean fever (FMF),mevalonate kinase deficiency (Hyper IgD syndrome), TNF receptor-associatedperiodic syndrome (TRAPS), familial Cold Autoinflammatory Syndrome (CAPS), type 1 interferonopathies,...

  5. Autoimmune diseases (AI), including among others: systemic lupus erythematosus (SLE), juvenile dermatomyositis (JDM), rheumatoid arthritis (RA),...

  6. Hyperinflammatory diseases, including among others: hemophagocyticlymphohistiocytosis (HLH), macrophage activation syndrome (MAS),infection-related cytokine storm (e.g. in the setting of COVID-19)

  7. Other unidentified or not yet identified systemic inflammatory conditions

  8. Blood sample for diagnostic purposes is planned and possibility to acquireadditional blood volume

Exclusion

Exclusion Criteria:

An individual who meets any of the following criteria will be excluded from participation in this study:

  1. Confirmed localized infection and/or good response to first-line antibiotictreatment

  2. Confirmed malignancy

Besides the above mentioned patients, volunteers that meet the requirements as a healthy individual are eligible for inclusion as controls.

Study Design

Total Participants: 2500
Treatment Group(s): 1
Primary Treatment: cytokine and lipidomic profiling
Phase:
Study Start date:
September 28, 2022
Estimated Completion Date:
December 31, 2029

Study Description

FEBRIS is a prospective, observational and multi-centric study involving 5 hospitals in Flanders, Belgium.

In this study, the researchers will us ehe FEBRIS Cytokine Profile Assay, which is a multiplex assay measuring pro- and anti-inflammatory cytokines in the blood of subjects. It has been developed in a retrospective cohort of human patients presenting systemic inflammatory disorders.

With this study, the researchers aim to prospectively validate the use of this assay in a cohort of patients that present signs reminiscent of systemic inflammation, including patients with antoinflammatory conditions, autoimmune disorders, hyperinflammatory syndromes (e.g. hemophagocytic lymphohistiocytosis and macrophage activation syndrome) and systemic infection. In parallel, serum amyloid A will be quantified in all patients. Lipidomics will be performed on patients with sufficient leftover sample. The researchers will integrate the data from these assays with clinical parameters at baseline and during follow-up to correlate markers with the clinical or genetic diagnosis, prognosis and effect of different therapeutics.

Patients fulfilling the inclusion criteria are eligible for longitudinal blood sampling (every 3-6 months) during the study period (maximum of 4 years). Additional clotted blood will only be collected when a blood sample for routine clinical purposes is performed.

In addition, patients initiated on biological therapeutics will be asked to complete questionnaires regarding health-related quality of life to document outcome and improve rational and cost-efficient use of additional investigations and treatment.

Connect with a study center

  • UZ Antwerpen

    Antwerp,
    Belgium

    Active - Recruiting

  • ZNA

    Antwerp,
    Belgium

    Site Not Available

  • UZ Brussel

    Brussels,
    Belgium

    Active - Recruiting

  • UGent

    Gent,
    Belgium

    Site Not Available

  • Ghent University Hospital

    Ghent, 9000
    Belgium

    Active - Recruiting

  • Jessa Hospital

    Hasselt,
    Belgium

    Active - Recruiting

  • UHasselt

    Hasselt,
    Belgium

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.